Nomic Bio partnered with Broad Clinical Labs to integrate Nomic’s Omni 1000 immunoassay platform into BCL’s omics and precision oncology offerings. The collaboration targets embedding proteomics data into genomic risk models, clinical trial workflows, and population-scale multiomic studies. Nomic’s Omni 1000 is built on nELISA bead-based multiplexing, with immunoassays covering more than 1,050 proteins and absolute quantification. The article also notes the technology approach is designed to avoid antibody cross-reactivity issues common in multiplex assays. BCL said initial development is underway, with jointly developed applications planned to begin offering in early 2027. Nomic positioned the partnership as a route toward quantitative, scalable proteomics that can match the usability of other core modalities. The key industry implication is improved comparability and operational scaling of proteomic biomarker workflows alongside genomic data in translational studies.